Clinical trials: Dermatitis Eczema
Atopic Dermatitis
Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD
This is a Phase 2 randomized, double-blind, parallel group, vehicle-controlled study to evaluate the safety and efficacy of topical ATx201 OINTMENT in adolescents and adults with mild to moderate Atopic Dermatitis
- Trial name
- NCT04339985
- Testing
- ATx201, ATx201 OINTMENT vehicle
- Where
- 10 sites in Bulgaria, Denmark and 1 more
- Volunteers
- 220 people
- Sponsor
- UNION therapeutics
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked.
- Trial name
- DISCOVER (NCT05590585)
- Testing
- dupilumab, Topical emollient (moisturizer)
- Where
- 30 sites in United States
- Volunteers
- 124 people
- Sponsor
- Regeneron Pharmaceuticals
Eczema
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.
- Trial name
- HANDEL (NCT00817063)
- Testing
- alitretinoin
- Where
- 70 sites in United States
- Volunteers
- 599 people
- Sponsor
- Stiefel, a GSK Company
Pruritus, Atopic Dermatitis
Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis
The purpose of this study is to assess the clinical activity on refractory moderate-to-severe pruritus of a single intravenous (IV) dose of REGN846 in adult patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01605708
- Testing
- REGN846
- Where
- 14 sites in Finland, Germany and 1 more
- Volunteers
- 19 people
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis, Atopic
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636.
- Trial name
- NCT07604324
- Testing
- DCY636
- Where
- Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis, Eczema
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADorable-1 (NCT05559359)
- Testing
- Lebrikizumab, Topical Corticosteroid (TCS)
- Where
- 85 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD), Eczema
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
- Conditions
- Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis
- Trial name
- NCT06723405
- Testing
- EVO301
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 71 people
- Sponsor
- Evommune, Inc.
Atopic Dermatitis
The Study of CM326 in Adult Subjects With Atopic Dermatitis
This is a open-label, multi-center study to evaluate the safety and efficacy of CM326 in atopic adrmatitis subjects.
- Trial name
- NCT05671445
- Testing
- CM326
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 330 subjects aged 12 to 75 years old with moderate to severe atopic dermatitis.
- Trial name
- NCT04875169
- Testing
- Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Extension Treatment Active Experimental: SHR0302 Dose#1
- Where
- 52 sites in Canada, China
- Volunteers
- 336 people
- Sponsor
- Reistone Biopharma Company Limited
Atopic Dermatitis, Atopic Dermatitis Eczema
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it).
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
- Trial name
- SIERRA1 (NCT07441395)
- Testing
- Soquelitinib
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Hand Eczema
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- NCT05906628
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 186 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients
Assess Hemay808 concentration of 1%/3%/7% for treatment of mild and moderate adult atopic dermatitis patients.
- Trial name
- NCT04352595
- Testing
- Hemay808
- Where
- 2 sites in China
- Volunteers
- 148 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Atopic Dermatitis
Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis
Atopic Dermatitis is a chronic inflammatory skin disease that affect 10 to 15% of children and 2 to 10% of adults. AD is characterised by an itchy skin eruption and may cover large parts of the body.
- Trial name
- NCT00882245
- Testing
- Vehicle ointment, Ointment
- Where
- 12 sites in Bulgaria, Finland and 1 more
- Volunteers
- 93 people
- Sponsor
- Serentis Ltd.
Atopic Dermatitis
A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
To demonstrate the therapeutic equivalence and safety of Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) and OPZELURA (Ruxolitinib) Cream in the treatment of mild-to-moderate atopic dermatitis
- Trial name
- NCT06673654
- Testing
- Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream
- Where
- United States
- Volunteers
- 476 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Atopic Dermatitis
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
This is a phase II, double blind study with ZEP-3NA 0.1% or 1% vs. vehicle-control in subjects with mild to moderate Atopic Dermatitis.
- Trial name
- NCT04307862
- Testing
- ZEP-3Na 0.1%, ZEP-3Na 1%
- Where
- 10 sites in Israel
- Volunteers
- 165 people
- Sponsor
- Shulov Innovate for Science Ltd. 2012
Atopic Dermatitis
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
The purpose of this study is to determine whether orally administered DS107 (1g and 2g doses) is effective in the treatment of moderate to severe atopic dermatitis.
- Trial name
- NCT02864498
- Testing
- DS107
- Where
- 2 sites in United States, South Africa
- Volunteers
- 321 people
- Sponsor
- DS Biopharma
Atopic Dermatitis
To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children
The purpose of this study was to evaluate the safety of the investigational study product and see how well it works to relieve signs and symptoms of children with mild to moderate Atopic Dermatitis (AD), also known as eczema, in…
- Trial name
- NCT00886587
- Testing
- F# 11054-010, F# 10495-053
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Dermatitis, Atopic
Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis
This study will evaluate efficacy and safety of GSK1070806 in moderate to severe atopic dermatitis (AtD) participants.
- Trial name
- NCT04975438
- Testing
- GSK1070806
- Where
- 11 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Dermatitis, Atopic
Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the efficacy and safety of 0.1% and 0.03% Tacrolimus ointment for 12 months in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT00691145
- Testing
- tacrolimus ointment
- Where
- 26 sites in Italy
- Volunteers
- 350 people
- Sponsor
- Astellas Pharma Inc
Dermatitis, Atopic
Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis
Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits the T-cell activation.
- Trial name
- NCT00121381
- Testing
- Pimecrolimus plus topical corticosteroid (TCS)
- Where
- 13 sites in United States
- Volunteers
- 400 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.